Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for TFX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -82.00M
March 31, 2026 -44.98M
December 31, 2025 -61.61M
September 30, 2025 756.34M
June 30, 2025 -23.67M
March 31, 2025 -59.52M
December 31, 2024 -119.12M
September 30, 2024 -174.82M
June 30, 2024 -56.54M
March 31, 2024 -71.45M
December 31, 2023 -237.50M
September 30, 2023 462.03M
June 30, 2023 -92.40M
March 31, 2023 -93.59M
December 31, 2022 -17.13M
September 30, 2022 -25.60M
June 30, 2022 -153.81M
March 31, 2022 -20.96M
December 31, 2021 -215.41M
September 30, 2021 -259.70M
June 30, 2021 -109.22M
March 31, 2021 -131.50M
December 31, 2020 338.94M
September 30, 2020 -296.22M
June 30, 2020 7.106M
Date Value
March 31, 2020 405.33M
December 31, 2019 -108.31M
September 30, 2019 -142.88M
June 30, 2019 -43.29M
March 31, 2019 -124.36M
December 31, 2018 -6.733M
September 30, 2018 -97.30M
June 30, 2018 -69.69M
March 31, 2018 -32.71M
December 31, 2017 -14.14M
September 30, 2017 237.72M
June 30, 2017 -103.59M
March 31, 2017 1.021B
December 31, 2016 -20.79M
September 30, 2016 -66.48M
June 30, 2016 -11.13M
March 31, 2016 -11.07M
December 31, 2015 -14.66M
September 30, 2015 -71.08M
June 30, 2015 -11.39M
March 31, 2015 11.55M
December 31, 2014 -13.67M
September 30, 2014 -13.96M
June 30, 2014 -254.57M
March 31, 2014 -5.50M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Globus Medical, Inc. -134.50M
Boston Scientific Corp. -410.00M
Alphatec Holdings, Inc. -19.53M
CONMED Corp. -46.23M
DexCom, Inc. -607.30M